Invesco Ltd. Has $10.55 Million Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Invesco Ltd. increased its holdings in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 37.9% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 769,284 shares of the company’s stock after buying an additional 211,503 shares during the period. Invesco Ltd. owned about 0.84% of Myriad Genetics worth $10,547,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in MYGN. KBC Group NV lifted its holdings in shares of Myriad Genetics by 132.8% during the fourth quarter. KBC Group NV now owns 5,845 shares of the company’s stock worth $80,000 after purchasing an additional 3,334 shares during the period. Inspire Advisors LLC lifted its holdings in Myriad Genetics by 48.1% during the 4th quarter. Inspire Advisors LLC now owns 11,226 shares of the company’s stock worth $154,000 after buying an additional 3,644 shares during the period. E Fund Management Co. Ltd. bought a new stake in shares of Myriad Genetics in the 4th quarter valued at about $161,000. Entropy Technologies LP acquired a new stake in shares of Myriad Genetics in the fourth quarter valued at about $178,000. Finally, Polymer Capital Management US LLC bought a new position in shares of Myriad Genetics during the fourth quarter worth about $179,000. 99.02% of the stock is owned by institutional investors.

Myriad Genetics Stock Up 0.4 %

Myriad Genetics stock opened at $7.43 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.73 and a debt-to-equity ratio of 0.05. The firm’s fifty day moving average price is $9.98 and its two-hundred day moving average price is $14.06. The firm has a market capitalization of $684.83 million, a price-to-earnings ratio of -5.72 and a beta of 1.87. Myriad Genetics, Inc. has a 1-year low of $7.28 and a 1-year high of $29.30.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The company had revenue of $210.60 million for the quarter, compared to analyst estimates of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same quarter last year, the firm posted ($0.12) EPS. On average, equities research analysts predict that Myriad Genetics, Inc. will post -0.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on MYGN shares. Bank of America decreased their target price on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating for the company in a research report on Monday, March 3rd. Stephens reiterated an “equal weight” rating and set a $20.00 price objective on shares of Myriad Genetics in a research report on Thursday, January 16th. The Goldman Sachs Group dropped their target price on shares of Myriad Genetics from $18.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, April 17th. Guggenheim downgraded Myriad Genetics from a “buy” rating to a “neutral” rating in a report on Wednesday, April 9th. Finally, Raymond James reissued an “outperform” rating and issued a $19.00 price objective (down from $27.00) on shares of Myriad Genetics in a research note on Tuesday, February 25th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Myriad Genetics currently has an average rating of “Hold” and a consensus target price of $20.61.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.